Milan - Delayed Quote EUR
CureVac N.V. (1CVAC.MI)
3.1860
+0.1260
+(4.12%)
At close: May 16 at 4:11:38 PM GMT+2
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
535,180
535,180
53,758
67,420
102,990
Cost of Revenue
105,829
105,829
124,366
183,993
238,195
Gross Profit
429,351
429,351
-70,608
-116,573
-135,205
Operating Expense
251,669
251,669
203,599
132,884
277,058
Operating Income
177,682
177,682
-274,207
-249,457
-412,263
Net Non Operating Interest Income Expense
12,357
12,357
15,448
-567
-235
Other Income Expense
842
842
-1,210
869
--
Pretax Income
190,881
190,881
-259,969
-249,155
-412,498
Tax Provision
28,695
28,695
198
-126
-782
Net Income Common Stockholders
162,186
162,186
-260,167
-249,029
-411,716
Diluted NI Available to Com Stockholders
162,186
162,186
-260,167
-249,029
-411,716
Basic EPS
0.72
0.72
-1.18
-1.32
-2.21
Diluted EPS
0.72
0.72
-1.18
-1.32
-2.21
Basic Average Shares
224,376.8300
224,376.8300
220,910.5090
189,074.9110
186,012.5860
Diluted Average Shares
225,270.4540
225,270.4540
220,910.5090
189,074.9110
186,012.5860
Total Operating Income as Reported
177,682
177,682
-274,207
-249,457
-412,263
Total Expenses
357,498
357,498
327,965
316,877
515,253
Net Income from Continuing & Discontinued Operation
162,186
162,186
-260,167
-249,029
-411,716
Normalized Income
161,470.5772
161,470.5772
-259,259.5000
-249,897.5605
-411,716
Interest Income
12,357
12,357
15,411
1,733
10,103
Interest Expense
0
0
0
2,299
10,338
Net Interest Income
12,357
12,357
15,448
-567
-235
EBIT
190,881
190,881
-259,969
-246,856
-402,160
EBITDA
209,690
209,690
-236,583
-223,115
-386,486
Reconciled Cost of Revenue
94,834
94,834
114,801
171,612
231,502
Reconciled Depreciation
18,809
18,809
23,386
23,741
15,674
Net Income from Continuing Operation Net Minority Interest
162,186
162,186
-260,167
-249,029
-411,716
Total Unusual Items Excluding Goodwill
842
842
-1,210
869
0
Total Unusual Items
842
842
-1,210
869
0
Normalized EBITDA
208,848
208,848
-235,373
-223,984
-386,486
Tax Rate for Calcs
0.0002
0.0002
0.0003
0
0
Tax Effect of Unusual Items
126.5772
126.5772
-302.5000
0.4395
0
12/31/2021 - 11/21/2023
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
F6T.DU Fate Therapeutics Inc
0.9210
+0.30%
1GDA.F Zevra Therapeutics, Inc.
7.45
+4.20%
P0F.F Egetis Therapeutics AB (publ)
0.2740
-7.90%
1TB0.SG Orphazyme AS
137.50
0.00%
8GN.F Cessatech A/S
1.6640
-2.23%
41X.SG Ardelyx Inc
2.9800
-1.06%
22UA.MU BioNTech SE
83.10
+0.79%
BLUE.MX bluebird bio, Inc.
80.00
0.00%
FTD.SG Financière de Tubize SA
121.60
+1.00%
CLAZF Claritas Pharmaceuticals, Inc.
0.0001
0.00%